SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Osteosarcoma; Sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 06 Jun 2017 Results (n=86) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 30 May 2017 Status changed from active, no longer recruiting to recruiting.
- 15 Mar 2017 Planned number of patients changed from 80 to 146.